Clinical trials: Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
This study will evaluate the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00547469
- Testing
- DDP733
- Where
- 69 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Dynogen Pharmaceuticals
Irritable Bowel Syndrome
Long Term Safety Study of Plecanatide
Multi-center, open-label, long-term safety study
- Trial name
- IBS-C (NCT02706483)
- Testing
- Plecanatide
- Where
- 204 sites in United States
- Volunteers
- 2,272 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation, Functional Constipation
IBS-C Questionnaire Study
The study is a multi-centre, observational study which enrolls 150 IBS-C patients and 150 non-IBS-C patients in China.
- Trial name
- NCT04968652
- Where
- 10 sites in China
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome With Constipation, Functional Constipation
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants…
- Trial name
- NCT04166058
- Testing
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 381 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in patients with C-IBS.
- Trial name
- NCT00258193
- Testing
- MD-1100 Acetate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.
- Trial name
- NCT00268879
- Testing
- Renzapride
- Where
- United Kingdom
- Volunteers
- 1,821 people
- Sponsor
- Alizyme
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation
This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation. The difference of responder rate between test group (10, 20 and 40mg) and placebo will be evaluated.
- Trial name
- YKP (NCT02082457)
- Testing
- YKP10811 5mg, YKP10811 20mg
- Where
- South Korea
- Volunteers
- 273 people
- Sponsor
- SK Chemicals Co., Ltd.
Irritable Bowel Syndrome With Constipation (IBS-C)
Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C
Irritable bowel syndrome (IBS) is a common functional bowel disorder that imposes a considerable burden on health-related quality of life (QOL) worldwide.
- Trial name
- RELAX (NCT05240521)
- Testing
- ARM A, ARM B
- Where
- 4 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Devintec Sagl
Constipation-predominant Irritable Bowel Syndrome
Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is a common disorder, defined by symptom-based diagnostic criteria. The pathogenesis is multifactorial and gut motor dysfunction is considered to be a contributing factor.
- Trial name
- NCT01085643
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cedars-Sinai Medical Center
Irritable Bowel Syndrome With Constipation
A Study of Virtual Reality and Linaclotide for IBS-C
The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication)…
- Trial name
- IBSC-VR (NCT05796388)
- Testing
- Virtual Reality
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Constipation Predominant Irritable Bowel Syndrome
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by…
- Trial name
- T3MPO-1 (NCT02621892)
- Testing
- Tenapanor
- Where
- 111 sites in United States
- Volunteers
- 606 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome Constipation Predominant
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel…
- Trial name
- NCT01056107
- Testing
- ROSE-010
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00215566
- Testing
- DDP733
- Where
- 15 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Dynogen Pharmaceuticals
Irritable Bowel Syndrome Characterized by Constipation
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
- Trial name
- IBS-C (NCT02493452)
- Testing
- Plecanatide
- Where
- 191 sites in United States
- Volunteers
- 1,135 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
Constipation Associated With Irritable Bowel Syndrome (IBS-C)
Multi-centre, double-blind, randomised, placebo-controlled, parallel group study.
- Trial name
- NCT00796354
- Testing
- MOVICOL, Sugar Pill
- Where
- 21 sites in Czechia, France and 5 more
- Volunteers
- 210 people
- Sponsor
- Norgine
Irritable Bowel Syndrome
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT04655599
- Testing
- Olorinab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome Characterized by Constipation
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.
- Trial name
- NCT02837783
- Testing
- Linaclotide
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome With Constipation
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
The goal of this clinical trial is to learn if plecanatide can improve bowel function and relieve symptoms of irritable bowel syndrome with constipation (IBS-C) in children and adolescents aged 6 to <18 years.
- Trial name
- (IBS-C) (NCT03596905)
- Testing
- Plecanatide
- Where
- 35 sites in United States
- Volunteers
- 218 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.
- Trial name
- NCT06553547
- Testing
- Tenapanor
- Where
- 20 sites in United States
- Volunteers
- 72 people
- Sponsor
- Ardelyx